Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Le Kremlin-Bicetre – page 219

3 418 clinical trials in Le Kremlin-Bicetre, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Le Kremlin-Bicetre at a glance
3 418
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 418 trials in Le Kremlin-Bicetre

Open in trial search

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen Cilag International
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Namilumab
  • Sponsor:Kinevant Sciences GmbH

Study of V940 and Pembrolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer After Surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effects of NX210c and Glucose in Adults with Amyotrophic Lateral Sclerosis (ALS)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glucose
  • Sponsor:Axoltis Pharma

Study on Benralizumab and Mepolizumab for Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) Receiving Standard Care

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Migraine+1

Not recruiting

Study of Eptinezumab as Add-on Treatment for Prevention of Migraine in Adults with Both Migraine and Medication Overuse Headache

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Eptinezumab
  • Sponsor:H. Lundbeck A/S

Sickle cell anaemia+1

Not recruiting

Study on Crizanlizumab for Adolescents and Adults with Sickle Cell Disease Experiencing Vaso-Occlusive Crises

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Crizanlizumab
  • Sponsor:Novartis Pharma AG

Plasma cell myeloma

Not recruiting

Study on Teclistamab and Drug Combination for Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Study of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ETOP IBCSG Partners Foundation

Follicular lymphoma

Not recruiting

Study of Zanubrutinib and Obinutuzumab for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Beigene Ltd.

Acute myeloid leukaemia+2

Not recruiting

Study on the Safety and Effectiveness of Quizartinib for Children and Young Adults with Acute Myeloid Leukemia (AML)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Quizartinib Dihydrochloride
  • Sponsor:Daiichi Sankyo Inc.

Study on the Safety and Effectiveness of Rilzabrutinib for Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP)

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Principia Biopharma Inc.

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Le Kremlin-Bicetre

What the registry says about research in the country

01 Bacterial Infections and Mycoses

Research in this area focuses on bacterial infections, especially severe ear, nose and throat diseases such as idiopathic purulent oedematous sinusitis in adults. The trials are aimed at evaluating whether treatment can improve symptoms and overall patient well-being.

  • Testing a treatment approach for persistent sinus infection
  • Assessing improvement in quality of life over time

In Kremlin Bicêtre, this work reflects a practical effort to better manage chronic ENT infection-related complaints.

02 Cardiovascular Diseases

Clinical research here also covers cardiovascular disease in patients hospitalized for septic shock with tachycardia and hypercontractility. The main goal is to evaluate whether controlling heart rate may help improve survival and clinical outcomes.

  • Studying a heart-rate-lowering strategy in septic shock
  • Comparing outcomes against standard care

These trials are designed to clarify whether better cardiovascular support can reduce risk in critically ill patients.

03 Otorhinolaryngologic Diseases

Another key research focus is otorhinolaryngology, with attention on sinusitis and related ENT disorders. The studies are looking at treatment effectiveness and changes in patient-reported symptoms during follow-up.

  • Measuring symptom relief in sinus disease
  • Tracking changes in disease-specific quality of life

This area highlights efforts to improve everyday functioning for patients living with ongoing nasal and sinus problems.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.